What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
Scott Kopetz mostly deals with Colorectal cancer, Internal medicine, Oncology, Cancer and Cancer research.
His Colorectal cancer research incorporates elements of Stage, Surgery, Microsatellite instability and Bioinformatics.
His research in Internal medicine focuses on subjects like Gastroenterology, which are connected to FOLFOX and Adenocarcinoma.
The concepts of his Oncology study are interwoven with issues in Cetuximab, Clinical trial, Survival rate, Irinotecan and Survival analysis.
The study incorporates disciplines such as Pathology and Hazard ratio in addition to Cancer.
His Cancer research study combines topics from a wide range of disciplines, such as Wnt signaling pathway, DNA, Proto-oncogene tyrosine-protein kinase Src, Disease and PI3K/AKT/mTOR pathway.
His most cited work include:
- The consensus molecular subtypes of colorectal cancer (1870 citations)
- Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study (897 citations)
- Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy (893 citations)
What are the main themes of his work throughout his whole career to date?
His primary scientific interests are in Colorectal cancer, Internal medicine, Oncology, Cancer research and Cancer.
His Colorectal cancer research includes elements of Bevacizumab, Microsatellite instability and Bioinformatics.
His study in the fields of Oxaliplatin, Chemotherapy and Disease under the domain of Internal medicine overlaps with other disciplines such as In patient.
In his research, Hepatectomy is intimately related to Survival rate, which falls under the overarching field of Oncology.
His Cancer research study integrates concerns from other disciplines, such as Mutation, Metastasis, PI3K/AKT/mTOR pathway, Circulating tumor DNA and Immunotherapy.
His studies in Cancer integrate themes in fields like Surgery, Proportional hazards model and Pathology.
He most often published in these fields:
- Colorectal cancer (65.20%)
- Internal medicine (52.13%)
- Oncology (45.51%)
What were the highlights of his more recent work (between 2019-2021)?
- Colorectal cancer (65.20%)
- Internal medicine (52.13%)
- Oncology (45.51%)
In recent papers he was focusing on the following fields of study:
Scott Kopetz spends much of his time researching Colorectal cancer, Internal medicine, Oncology, Cancer research and Cancer.
The KRAS research Scott Kopetz does as part of his general Colorectal cancer study is frequently linked to other disciplines of science, such as In patient, therefore creating a link between diverse domains of science.
His biological study spans a wide range of topics, including Cetuximab, Monoclonal antibody, Irinotecan, Bevacizumab and Advanced colorectal cancer.
His Cancer research research is multidisciplinary, relying on both Immune checkpoint, Immunotherapy, Transcriptome, Mutant and DNA mismatch repair.
Scott Kopetz combines subjects such as Immunogenic cell death, Cancer cell, Microsatellite instability and Mutation with his study of DNA mismatch repair.
His study looks at the relationship between Hazard ratio and topics such as Proportional hazards model, which overlap with Metastasis.
Between 2019 and 2021, his most popular works were:
- Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma (53 citations)
- Biomarker-guided therapy for colorectal cancer: strength in complexity (50 citations)
- Non-coding RNAs in GI cancers: from cancer hallmarks to clinical utility. (38 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
Scott Kopetz focuses on Colorectal cancer, Internal medicine, Oncology, Cancer research and Immunotherapy.
Scott Kopetz is studying Oxaliplatin, which is a component of Colorectal cancer.
His work carried out in the field of Oncology brings together such families of science as Encorafenib, Cetuximab, Irinotecan, FOLFIRI and Binimetinib.
His Cancer research research includes themes of Carcinogenesis, Cancer, Phenotype and DNA mismatch repair.
His Immunotherapy research is multidisciplinary, incorporating elements of Human leukocyte antigen, Antigen and Pancreatic cancer.
His Proportional hazards model research incorporates themes from Young adult, Metastasis, Gastroenterology and Chemotherapy.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
